It is highly similar to the reference product Eylea® (aflibercept ... with or without occlusion may occur following intravitreal injections. Patients and/or caregivers should be instructed ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today a settlement and license agreement with ...

BRIDGEWATER, N.J. and BENGALURU, Karnataka, India, April 15, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon ...

William Blair initiated coverage of Kalaris Therapeutics (KLRS) with an Outperform rating and $21 fair value estimate. Kalaris is a ...

Similar to Vabysmo, it is also available in both vials and prefilled syringes, and administered via intravitreal injection. Eylea, along with a higher-dose version at 8mg, generated global sales ...

Authors of the study believe this potential will provide clinicians with valuable information about patient responses to treatment.

One trial evaluated sozinibercept in combination with aflibercept 2 mg (Eylea), the other in combination ... The aflibercept trial, known as COAST, evaluated intravitreal sozinibercept every ...